Generate Biomedicines (NASDAQ:GENB) Sets New 12-Month High – Still a Buy?

Generate Biomedicines Inc (NASDAQ:GENB) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $15.98 and last traded at $15.5890, with a volume of 18490 shares. The stock had previously closed at $15.49.

Generate Biomedicines News Summary

Here are the key news stories impacting Generate Biomedicines this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $25 price target on Generate Biomedicines, reinforcing a bullish long-term view even after mixed earnings revisions.
• Positive Sentiment: The stock was also supported by market data showing it trading near its 52-week high, which can signal improving investor sentiment and momentum.
• Neutral Sentiment: NASDAQ posted an institutional-holdings page for Generate Biomedicines, which is generally informational and not a direct fundamental catalyst. Institutional Holdings
• Neutral Sentiment: Short-interest data showed 0 shares reported, which does not provide a meaningful directional signal for the stock.
• Negative Sentiment: HC Wainwright lowered several earnings estimates for Generate Biomedicines, including FY2026 and multiple quarterly forecasts, highlighting continued expected losses.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on GENB shares. Morgan Stanley started coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating and a $20.00 price objective on the stock. Piper Sandler started coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 price target on the stock. The Goldman Sachs Group began coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $26.00 price objective for the company. HC Wainwright increased their target price on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, Zacks Research upgraded shares of Generate Biomedicines to a “hold” rating in a report on Wednesday, March 25th. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

Generate Biomedicines Trading Up 5.7%

The business has a 50 day moving average price of $12.74.

Generate Biomedicines (NASDAQ:GENB) last issued its earnings results on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.